NOVAVAX INC
Close on Oct 19, 2026
- Market cap
- $1.78B
- P/E (TTM)
- –
- Dividend yield
- –
About Novavax
Biological Products, (No Diagnostic Substances), SIC 2836
Novavax, Inc. is a biotechnology company focused on developing and commercializing vaccines to prevent serious infectious diseases. The company utilizes a proprietary recombinant protein nanoparticle technology combined with its Matrix-M adjuvant to stimulate immune responses. Its commercial and pipeline portfolio includes authorized coronavirus vaccines, malaria vaccines, and combination vaccine candidates such as COVID-19 and influenza formulations. Novavax collaborates with and licenses its technology to global pharmaceutical partners, healthcare organizations, and sovereign governments for vaccine manufacturing, distribution, and pipeline integration.
The company operates globally through strategic agreements, supply contracts, and partner networks. Novavax manufactures its Matrix-M adjuvant in Uppsala, Sweden, and relies on external contract manufacturers for large-scale production, formulation, and distribution. Its partner-led malaria vaccine is available across multiple international markets, including twenty-four countries as of early 2026. Novavax maintains its principal executive offices and headquarters in Gaithersburg, Maryland.
Summary of the business section of Novavax's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NOVAVAX INC
- Founded
- 1987
- Headquarters
- Gaithersburg, MD
- Address
- 21 Firstfield Rd
- Phone
- (240) 268-2000
- Website
- es.novavax.com
- Employees
- 749, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, Tysons, Virginia
Stock & identifiers
- Ticker
- NVAX
- Exchange
- Nasdaq
- Shares outstanding
- 165M, Jul 31, 2026
- Public float
- $1.02B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-20 reverse, May 10, 2019; 1-for-20 reverse, May 10, 2019
- SEC CIK
- 1000694
- CUSIP
- 670002401
- ISIN
- US6700024010
- LEI
- 529900J4GJHPEPQ23205
- EIN
- 22-2816046
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John C. Jacobs | President and CEO, Director | 225,680 |
| Robert Edward Walker | EVP, R&D | 34,386 |
| Elaine O'Hara | EVP, Chief Strategy Officer | 157,071 |
| James Patrick Kelly | EVP, CFO and Treasurer | 130,599 |
| Mark J. Casey | EVP, Chief Legal Officer | 101,445 |
| Ruxandra Draghia-Akli | EVP, Research & Development | 23,563 |
| John Trizzino | President and COO | 82,015 |
| John W. Shiver | Director | 7,947 |
| David M. Mott | Director | 79,770 |
| Rachel K. King | Director | 45,170 |
| Margaret G. McGlynn | Director | 44,468 |
| Gregg H. Alton | Director | 47,685 |
| Richard Douglas | Director | 73,220 |
| Charles W. Newton | Director | 9,520 |
| Richard J. Rodgers | Director | 47,370 |
| James F. Young | Director | 53,260 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 John C. Jacobs | $8.86M | $6.31M | $2.70M | $6 | $85 |
| FY2025 John C.Jacobs | $8.86M | $6.31M | $2.70M | $6 | $85 |
| FY2024 John C. Jacobs | $5.09M | $7.11M | $1.54M | $7 | $60 |
| FY2024 John C.Jacobs | $5.09M | $7.11M | $1.54M | $7 | $60 |
| FY2023 John C.Jacobs | $7.27M | $3.78M | $1.71M | $4 | $59 |
| FY2023 Stanley C.Erck | $3.83M | $144.98K | $1.71M | $4 | $59 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We have a team of approximately 749 employees as of December 31, 2025.”
Corporate history
Events identified from SEC filings